Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:01541's EV-to-FCF is ranked worse than 100% of 337
companies
in the Biotechnology industry
Industry Median: 16.61
vs HKSE:01541: -1.96
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ImmuneOnco Biopharmaceuticals (Shanghai)'s PE Ratio (TTM) for today is calculated as:
ImmuneOnco Biopharmaceuticals (Shanghai)'s share price for today is HK$3.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.581.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
ImmuneOnco Biopharmaceuticals (Shanghai) EV-to-FCF Related Terms
ImmuneOnco Biopharmaceuticals (Shanghai) EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01541 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) EV-to-FCF vs Biotechnology Industry
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Enterprise Value is HK$437.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. ImmuneOnco Biopharmaceuticals (Shanghai)'s Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-223.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a EV-to-FCF of -1.96 as of Aug. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #999999 out of 337 companies in the Biotechnology industry.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-FCF too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current EV-to-FCF is -1.96. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #999999 out of 337 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #999999 out of 337 companies for EV-to-FCF. This places ImmuneOnco Biopharmaceuticals (Shanghai) in the lower half of its industry. The industry median EV-to-FCF is 16.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.61, based on 337 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ImmuneOnco Biopharmaceuticals (Shanghai)'s current EV-to-FCF is -1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a current EV-to-FCF of -1.96. The current EV-to-FCF is -1.96. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541), the current EV-to-FCF is -1.96 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score
Get the complete analysis for HKSE:01541
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01541 has been successfully added to your 
